Sugi Predict

Sugi Predict / Compounds / SCHEMBL9962272

SCHEMBL9962272

SCHEMBL9962272

CC(C)c1ccccc1S(=O)(=O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.60
▸ MMP2 P08253 4/20 0.57
▸ MMP9 P14780 4/20 0.57
▸ MMP8 P22894 4/20 0.57
▸ MMP12 P39900 4/20 0.57
▸ MMP13 P45452 4/20 0.57
▸ MMP14 P50281 4/20 0.57
▸ MMP16 P51512 4/20 0.57
▸ MMP1 P03956 2/20 0.57
▸ HTR6 P50406 5/20 0.52
▸ MMP3 P08254 3/20 0.51
▸ HTR2A P28223 2/20 0.48
▸ HTR2C P28335 2/20 0.48
▸ KCNH2 Q12809 2/20 0.48
▸ KMT2A Q03164 1/20 0.46
▸ TSHR P16473 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ PTGDR2 Q9Y5Y4 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ CA12 O43570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9379437 0.87 HSD11B1 (0.54) HSD11B1MMP2MMP9MMP8MMP12
SCHEMBL7266582 0.85 HSD11B1 (0.62) HSD11B1MMP2MMP9MMP8MMP12
SCHEMBL28775082 0.85 HSD11B1 (0.48) HSD11B1MMP2MMP9MMP8MMP12
SCHEMBL28941489 0.85 HTR2A (0.64) HSD11B1MMP2MMP9MMP8MMP12
SCHEMBL7268074 0.83 MMP2 (0.67) HSD11B1MMP2MMP9MMP8MMP12
Oxalic Acid SCHEMBL8940966 0.82 MMP2 (0.51) HSD11B1MMP2MMP9MMP8MMP12
SCHEMBL10179740 0.82 MMP2 (0.51) HSD11B1MMP2MMP9MMP8MMP12
SCHEMBL9228368 0.82 MMP2 (0.82) HSD11B1MMP2MMP9MMP8MMP12
SCHEMBL4617377 0.80 CNR2 (0.46) HSD11B1MMP2MMP9MMP8MMP12
SCHEMBL22927502 0.79 HSD11B1 (0.47) HSD11B1MMP2MMP9MMP8MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230046457-A1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN MA INC. 2023-02-16 — — US disclosed
US-20200399283-A1 BRUTON'S TYROSINE KINASE INHIBITORS VIRACTA THERAPEUTICS, INC. 2020-12-24 — — US disclosed
US-10577374-B2 Bruton's tyrosine kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2020-03-03 — — US disclosed
US-20180065974-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-03-08 — — US disclosed
US-20180065974-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-03-08 — — US disclosed
US-9790229-B2 Bruton's tyrosine kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2017-10-17 — — US disclosed
US-20160376281-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2016-12-29 — — US disclosed
US-9249146-B2 Bruton'S tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-02-02 — — US disclosed
US-9029359-B2 Heteroaryl Btk inhibitors BIOGEN IDEC MA, INC. (US) 2015-05-12 — — US disclosed
US-20140309212-A1 BRUTON'S TYROSINE KINASE INHIBITORS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2014-10-16 — — US disclosed
US-8785440-B2 Bruton's tyrosine kinase inhibitors BIOGEN IDEC MA, INC. (US) 2014-07-22 — — US disclosed
US-20130244122-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME ONUKI MASAMICHI (JP) 2013-09-19 — — US disclosed
US-20120219866-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS-ELECTROLYTE BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2012-08-30 — — US disclosed
EP-2475041-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE BATTERY COMPRISING SAME Mitsubishi Chemical Corporation (JP) 2012-07-11 — — EP disclosed
US-20120157442-A1 HETEROARYL BTK INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2012-06-21 — — US disclosed
US-20120157443-A1 BRUTON'S TYROSINE KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2012-06-21 — — US disclosed
WO-2011029043-A1 HETEROARYL BTK INHIBITORS BIOGEN IDEC MA INC. (US) 2011-03-10 — — WO disclosed
WO-2011029046-A1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2011-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157442-A1 HETEROARYL BTK INHIBITORS BTK, LYN, SYK HSD11B1 3165/4885MMP2 4341/4885MMP9 4043/4885
US-20230046457-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK HSD11B1 3609/4885MMP2 3961/4885MMP9 3162/4885
US-20160376281-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK HSD11B1 3609/4885MMP2 3961/4885MMP9 3162/4885
US-20140309212-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK HSD11B1 3609/4885MMP2 3961/4885MMP9 3162/4885
US-20200399283-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK HSD11B1 3609/4885MMP2 3961/4885MMP9 3162/4885
US-20120157443-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK HSD11B1 3609/4885MMP2 3961/4885MMP9 3162/4885
US-10577374-B2 Bruton's tyrosine kinase inhibitors BTK, ABL1, SYK HSD11B1 3609/4885MMP2 3961/4885MMP9 3162/4885
US-20180065974-A1 BRUTON'S TYROSINE KINASE INHIBITORS BTK, ABL1, SYK HSD11B1 3609/4885MMP2 3961/4885MMP9 3162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.